Susanna Y. Cheng
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.
Journal: Future oncology (London, England)
Published: July 16, 2026
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
Journal: Targeted oncology
Published: September 02, 2025
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
Journal: Clinical genitourinary cancer
Published: July 12, 2024
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
Journal: BMJ open
Published: March 29, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 13, 2023
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Journal: The New England journal of medicine
Published: October 23, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
Journal: JTO clinical and research reports
Published: June 30, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 10, 2023
EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report.
Journal: Current oncology (Toronto, Ont.)
Published: March 23, 2022
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: January 08, 2021
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: April 17, 2018
Last Updated: 09/26/2026